A client receiving chemotherapy is at risk for tumor lysis syndrome.
Which lab finding is expected?

Choice A rationale

Hospice care primarily emphasizes comfort and symptom management rather than aggressive disease treatment. Its focus shifts from curative interventions to enhancing the patient's quality of life during the final stages of a terminal illness. This approach ensures dignity and relief from suffering, prioritizing holistic well-being over disease eradication.

Choice B rationale

Hospice care specifically caters to individuals who are no longer pursuing curative treatments. It is designed for patients with a life expectancy of six months or less, as certified by a physician, who have opted for comfort-focused care instead of aggressive medical interventions aimed at prolonging life.

Choice C rationale

Palliative care offers symptom relief and support at any stage of a serious illness, irrespective of prognosis or whether curative treatments are still being pursued. Hospice care, conversely, is a specific type of palliative care reserved exclusively for patients nearing the end of life who have chosen to forgo curative treatments.

Choice D rationale

Hospice care provides comprehensive comfort and support services to patients in the final stages of a terminal illness, typically when curative treatments are no longer effective or desired. Palliative care, however, is a broader approach that can be initiated at any point during a serious illness, even alongside curative treatments, to improve quality of life.

Choice A rationale

Promoters are substances that do not directly cause DNA mutations but accelerate the growth and proliferation of cells that have already undergone an initiating mutation. They create an environment favorable for the clonal expansion of pre-malignant cells, leading to tumor development. This distinguishes them from initiators, which are directly genotoxic and cause the initial DNA damage.

Choice B rationale

Promoters do not help prevent cancer cells from invading other cells. Instead, their action is to enhance the proliferation of transformed cells, thereby contributing to tumor growth and progression. Mechanisms that prevent invasion typically involve modulating cell adhesion, extracellular matrix degradation, or cell motility, which are distinct from promoter activities.

Choice C rationale

Promoters are involved in carcinogenesis, the development of cancer, and do not directly enhance the effect of chemotherapy drugs. Chemotherapy drugs primarily target rapidly dividing cells or specific molecular pathways within cancer cells to induce cytotoxicity or inhibit growth. The mechanisms of promoters are distinct from those involved in modulating drug efficacy.

Choice D rationale

Promoters primarily act by increasing the rate of cell division and clonal expansion of initiated cells within the local environment, contributing to primary tumor growth. While tumor growth is a prerequisite for metastasis, promoters do not directly facilitate the complex processes of invasion, intravasation, survival in circulation, extravasation, and colonization in distant sites that characterize metastasis.